Biolyst › OCSCash & investments
CHF 82M
Oculis Holding AG is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Clinical Study Evaluating Licaminlimab for Dry Eye Disease on December 15, 2026. There are 2 upcoming events on record.
Cash runway is approximately 13.6 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
Across 8 concluded trials, 88% reached completion rather than being terminated or withdrawn.
Track OCS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open OCS in the tracker
Recent history
Date Event Type Phase
September 30, 2026
6-K filed: Foreign issuer report Filing
—
August 10, 2026
6-K filed: Foreign issuer report Filing
—
August 6, 2026
6-K filed: Foreign issuer report Filing
—
June 25, 2026
6-K filed: Foreign issuer report Filing
—
June 1, 2026
6-K filed: Foreign issuer report Filing
—
May 14, 2026
6-K filed: Foreign issuer report Filing
—
May 11, 2026
6-K filed: Foreign issuer report Filing
—
April 21, 2026
6-K filed: Foreign issuer report Filing
—
April 10, 2026
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) Trial Milestone
Phase 2/Phase 3
April 2, 2026
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) Trial Milestone
Phase 3
March 4, 2026
Results filed (20-F) Earnings
—
March 4, 2026
6-K filed: Foreign issuer report Filing
—
March 3, 2026
6-K filed: Foreign issuer report Filing
—
November 10, 2025
6-K filed: Foreign issuer report Filing
—
October 31, 2025
6-K filed: Foreign issuer report Filing
—
October 29, 2025
6-K filed: Foreign issuer report Filing
—
October 6, 2025
6-K filed: Foreign issuer report Filing
—
August 21, 2025
6-K filed: Foreign issuer report Filing
—
August 1, 2025
6-K filed: Foreign issuer report Filing
—
June 5, 2025
6-K filed: Foreign issuer report Filing
—
May 9, 2025
6-K filed: Foreign issuer report Filing
—
May 8, 2025
6-K filed: Foreign issuer report Filing
—
April 15, 2025
6-K filed: Foreign issuer report Filing
—
September 16, 2024
OCS-05 in Patients With Optic Neuritis Trial Milestone
Phase 2
May 2, 2024
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery Trial Milestone
Phase 3
March 27, 2024
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease Trial Milestone
Phase 2
June 22, 2023
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery Trial Milestone
Phase 3
January 31, 2020
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients Trial Milestone
Phase 2
March 28, 2019
Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema Trial Milestone
Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.